<H1>Chapter DOI: 10.1208/aapsj070237<br/>Cited-By Count: 19</H1><table border="1" width="30%"><tr><td>Total References</td><td>42</td></tr><tr><td>Springer references</td><td>26</td></tr><tr><td>Non Springer references</td><td>16</td></tr><tr><td>BibStructured Count</td><td width="10%">42</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>30</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>6</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>2</td></tr><tr><td>DOI Obtained For Non Springer</td><td>5</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>7</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Sheiner LB, Rosenberg B, Marathe V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1977;5:445&#8211;479.</td><td><a href=http://dx.doi.org/10.1007/BF01061728>10.1007/BF01061728</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1981;9:635&#8211;651.</td><td><a href=http://dx.doi.org/10.1007/BF01061030>10.1007/BF01061030</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine pharmacokinetic data.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1982;11:303&#8211;319.</td><td><a href=http://dx.doi.org/10.1007/BF01061870>10.1007/BF01061870</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.<Emphasis Type="Italic">J Pharmacokinet Biopharm.</Emphasis> 1980;8:553&#8211;571.</td><td><a href=http://dx.doi.org/10.1007/BF01060053>10.1007/BF01060053</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Peck CC, Beal SL, Sheiner LB, Nichols AI. Extended least squares nonlinear regression: a possible solution to the &#8220;choice of weights&#8221; problem in analysis of individual pharmacokinetic data.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1984;12:545&#8211;558.</td><td><a href=http://dx.doi.org/10.1007/BF01060132>10.1007/BF01060132</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.<Emphasis Type="Italic">J Pharmacokinet Biopharm.</Emphasis> 1985;13:185&#8211;201.</td><td><a href=http://dx.doi.org/10.1007/BF01059398>10.1007/BF01059398</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Vozeh S, Katz G, Steiner V, Follath F. Population pharmacokinetic parameters in patients treated with oral mexiletine.<Emphasis Type="Italic">Eur J Clin Pharmacol.</Emphasis> 1982;23:445&#8211;451.</td><td><a href=http://dx.doi.org/10.1007/BF00605996>10.1007/BF00605996</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1984;9:545&#8211;554.</td><td><a href=http://dx.doi.org/10.2165/00003088-198409060-00004>10.2165/00003088-198409060-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Grasela T, Donn SM. Neonatal population pharmacokinetics for phenobarbital derived from routine clinical data.<Emphasis Type="Italic">Dev Pharmacol Ther</Emphasis>. 1985;8:374&#8211;383.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Grasela TH, Antal EJ, Ereshefsky L, Wells BG, Evans RL Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.<Emphasis Type="Italic">Clin Pharmacol Ther.</Emphasis> 1987;42:433&#8211;441.</td><td><a href=http://dx.doi.org/10.1038/clpt.1987.174>10.1038/clpt.1987.174</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.<Emphasis Type="Italic">AAPS PharmSci.</Emphasis> 2002;4:E27.</td><td><a href=http://dx.doi.org/10.1208/ps040427>10.1208/ps040427</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEN population analysis: application to midazolam.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1991;19:377&#8211;384.</td><td><a href=http://dx.doi.org/10.1007/BF01061662>10.1007/BF01061662</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Mandema J, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1992;20:511&#8211;528.</td><td><a href=http://dx.doi.org/10.1007/BF01061469>10.1007/BF01061469</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibBook</td><td>Hastie TJ, Tibshirani RJ.<Emphasis Type="Italic">Generalized Additive Models</Emphasis>. New York: Chapman and Hall. 1990.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/9781118445112.stat03141>10.1002/9781118445112.stat03141</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Bruno R, Vivier N, Vergniol JC, DePhillips SL, Montay G, Sheiner LB. A population model for docetaxel (Taxotere<Superscript>&#174;</Superscript>): model building and validation.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1996;24:153&#8211;172.</td><td><a href=http://dx.doi.org/10.1007/BF02353487>10.1007/BF02353487</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1993;21:735&#8211;750.</td><td><a href=http://dx.doi.org/10.1007/BF01113502>10.1007/BF01113502</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Laporte-Simitsidis S, Girard P, Mismetti P, Chabaud S, Decousus H, Boissel JP. Inter-study variability in population pharmacokinetic analysis: when and how to estimate it?.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 2000;89:155&#8211;166.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1520-6017(200002)89:2&lt;155::AID-JPS3&gt;3.0.CO;2-2>10.1002/(SICI)1520-6017(200002)89:2&lt;155::AID-JPS3&gt;3.0.CO;2-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.<Emphasis Type="Italic">J Pharmacokinet Biopharm.</Emphasis> 1994;22:165&#8211;176.</td><td><a href=http://dx.doi.org/10.1007/BF02353542>10.1007/BF02353542</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibBook</td><td>Verbeke G, Molenberghs G.<Emphasis Type="Italic">Linear Mixed Models in Practice: A SAS-Oriented Approach</Emphasis>. New York: Springer Verlag: 1997.</td><td><a href=http://dx.doi.org/10.1007/978-1-4612-2294-1>10.1007/978-1-4612-2294-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, Year, ChapterTitle, BookTitle</td><td>CrossRef</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn.</Emphasis> 2001;28:231&#8211;252.</td><td><a href=http://dx.doi.org/10.1023/A:1011527125570>10.1023/A:1011527125570</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Wahlby U, Bouw MR, Jonsson EN, Karlsson MO. Assessment of type I error rates for statistical sub-model in NONMEM.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn.</Emphasis> 2002;29:251&#8211;269.</td><td><a href=http://dx.doi.org/10.1023/A:1020254823597>10.1023/A:1020254823597</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Stram DO, Lee JW. Variance components testing in the longitudinal mixed effects model.<Emphasis Type="Italic">Biometries</Emphasis>. 1994;50:1171&#8211;1177.</td><td><a href=http://dx.doi.org/10.2307/2533455>10.2307/2533455</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibBook</td><td>Pinheiro JC, Bates DM.<Emphasis Type="Italic">Mixed-Effect Models in S and S-Plus</Emphasis>. New York: Springer Verlag; 2000.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Aarons L, Balant LP, Mentre F, Morselli PL, Rowland M Steimer J-L, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies.<Emphasis Type="Italic">Eur J Clin Pharmacol.</Emphasis> 1996;49:251&#8211;254.</td><td><a href=http://dx.doi.org/10.1007/BF00226323>10.1007/BF00226323</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Kowalski K, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulation: a case study.<Emphasis Type="Italic">Stat Med.</Emphasis> 2001;20:75&#8211;91.</td><td><a href=http://dx.doi.org/10.1002/1097-0258(20010115)20:1&lt;75::AID-SIM602&gt;3.0.CO;2-C>10.1002/1097-0258(20010115)20:1&lt;75::AID-SIM602&gt;3.0.CO;2-C</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Lee PID. Design and power of a population pharmacokinetic study.<Emphasis Type="Italic">Pharm Res.</Emphasis> 2001; 18:75&#8211;82.</td><td><a href=http://dx.doi.org/10.1023/A:1011030827847>10.1023/A:1011030827847</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Green D, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn.</Emphasis> 2003;30:145&#8211;161.</td><td><a href=http://dx.doi.org/10.1023/A:1024467714170>10.1023/A:1024467714170</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Duffull SB, Retout S, Mentre F. The use of simulated annealing for finding optimal population designs.<Emphasis Type="Italic">Comput Methods Programs Biomed.</Emphasis> 2002; 69:25&#8211;35.</td><td><a href=http://dx.doi.org/10.1016/S0169-2607(01)00178-X>10.1016/S0169-2607(01)00178-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1998;26:207&#8211;246.</td><td><a href=http://dx.doi.org/10.1023/A:1020561807903>10.1023/A:1020561807903</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1999;16:709&#8211;717.</td><td><a href=http://dx.doi.org/10.1023/A:1018828709196>10.1023/A:1018828709196</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Hartford A, Davidian M. Consequences of misspecifying assumptions in nonlinear mixed effects models.<Emphasis Type="Italic">Comp Stat Data Anal</Emphasis>. 2000;34:139&#8211;164.</td><td><a href=http://dx.doi.org/10.1016/S0167-9473(99)00076-6>10.1016/S0167-9473(99)00076-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Ette EI, Williams PJ, Kim YH, Lane JR, Liu M-J, Capparelli EV, Model appropriateness and pharmacokinetic modeling.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2003;43:610&#8211;623.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C Sanderlink G-J, Becker R, Antman EM. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 2003;56:407&#8211;414.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2003.01904.x>10.1046/j.1365-2125.2003.01904.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2003;43:698&#8211;710.</td><td><a href=http://dx.doi.org/10.1177/0091270003254802>10.1177/0091270003254802</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Holford NHG. A size standard for pharmacokinetics.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1996;30:329&#8211;332.</td><td><a href=http://dx.doi.org/10.2165/00003088-199630050-00001>10.2165/00003088-199630050-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Grasmader K, Verwohlt PL, Kuhn K-U, Dragicevic A, von Widdern O, Zobel A, Hiemke C, Rietschel M, Maier W, Jaehde U, Rao ML. Population pharmacokinetic analysis of mirtazapine.<Emphasis Type="Italic">Eur J Clin Pharmacol</Emphasis>. 2004;60:473&#8211;480.</td><td><a href=http://dx.doi.org/10.1007/s00228-004-0737-0>10.1007/s00228-004-0737-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibChapter</td><td>Beal SL, Sheiner LB. Methodology of population pharmacokinetics. In: Garrett ER, Hirtz JL, eds.<Emphasis Type="Italic">Drug Fate and Metabolism: Methods and Techniques. Vol. 5</Emphasis> New York: Marcel Dekker, Inc; 1985;135&#8211;183.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Sheiner LB, Ludden TM. Population pharmacokinetics/ pharmacodynamics.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 1992;32:185&#8211;209.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Tett S, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: an underutilized resource.<Emphasis Type="Italic">Drug Inf J</Emphasis>. 1998;32:693&#8211;710.</td><td><a href=http://dx.doi.org/10.1177/009286159803200310>10.1177/009286159803200310</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR40</td><td>BibBook</td><td>Davidian M, Giltinan DM.<Emphasis Type="Italic">Nonlinear Models for Repeated Measures Data</Emphasis>. New York: Chapman and Hall; 1995.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41</td><td>BibBook</td><td>Verbeke G, Molenberghs G.<Emphasis Type="Italic">Linear Mixed Models for Longitudinal Data</Emphasis>. New York: Springer-Verlag, 2000.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-1-4612-2294-1_3>10.1007/978-1-4612-2294-1_3</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, BookTitle</td><td>CrossRef</td></tr><tr><td>CR42</td><td>BibBook</td><td>US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry.<Emphasis Type="Italic">Population Pharmacokinetics</Emphasis>. Washington, DC: Food and Drug Administration; 1999.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-3-319-27883-4_4>10.1007/978-3-319-27883-4_4</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr></table>